Marshall Wace
DGX icon

Marshall Wace’s Quest Diagnostics DGX Stock Holding History

Marshall Wace’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.3M Buy
200,278
+107,061
+115% +$20.8M 0.04% 447
2025
Q4 		$16.2M Sell
93,217
-463,938
-83% -$84.5M 0.01% 704
2025
Q3 		$106M Buy
557,155
+352,072
+172% +$62.5M 0.11% 158
2025
Q2 		$36.8M Sell
205,083
-278,204
-58% -$48.3M 0.04% 376
2025
Q1 		$81.8M Sell
483,287
-312,794
-39% -$51.4M 0.1% 172
2024
Q4 		$120M Sell
796,081
-204,584
-20% -$31.8M 0.14% 115
2024
Q3 		$155M Buy
1,000,665
+811,640
+429% +$121M 0.19% 85
2024
Q2 		$25.9M Sell
189,025
-397,174
-68% -$54.4M 0.03% 421
2024
Q1 		$78M Buy
586,199
+417,862
+248% +$54.2M 0.12% 164
2023
Q4 		$23.2M Buy
168,337
+166,348
+8,363% +$21.9M 0.04% 434
2023
Q3 		$242K Buy
+1,989
New +$265K ﹤0.01% 1941
2023
Q2 		– Sell
-19,827
Closed -$2.81M – 2556
2023
Q1 		$2.81M Sell
19,827
-90,395
-82% -$12.9M 0.01% 1274
2022
Q4 		$17.2M Buy
110,222
+86,337
+361% +$12.4M 0.04% 516
2022
Q3 		$2.93M Buy
23,885
+7,085
+42% +$933K 0.01% 1769
2022
Q2 		$2.23M Sell
16,800
-30,991
-65% -$4.22M ﹤0.01% 1909
2022
Q1 		$6.54M Buy
47,791
+9,389
+24% +$1.31M 0.01% 1179
2021
Q4 		$6.64M Sell
38,402
-57,992
-60% -$8.82M 0.01% 1162
2021
Q3 		$14M Buy
96,394
+822
+0.9% +$120K 0.06% 384
2021
Q2 		$12.6M Buy
95,572
+61,828
+183% +$8.1M 0.06% 378
2021
Q1 		$4.33M Sell
33,744
-27,558
-45% -$3.4M 0.02% 917
2020
Q4 		$7.3M Buy
+61,302
New +$7.47M 0.04% 444
2020
Q3 		– Sell
-160,517
Closed -$18.3M – 1638
2020
Q2 		$18.3M Sell
160,517
-496,688
-76% -$52.7M 0.13% 167
2020
Q1 		$52.8M Sell
657,205
-49,135
-7% -$5.09M 0.53% 38
2019
Q4 		$75.4M Sell
706,340
-61,309
-8% -$6.39M 0.52% 33
2019
Q3 		$82.2M Buy
767,649
+496,119
+183% +$50.9M 0.65% 20
2019
Q2 		$27.6M Buy
271,530
+25,916
+11% +$2.49M 0.23% 92
2019
Q1 		$22.1M Sell
245,614
-238,045
-49% -$20.6M 0.21% 103
2018
Q4 		$40.3M Sell
483,659
-1,041,900
-68% -$97.7M 0.41% 43
2018
Q3 		$165M Buy
1,525,559
+781,703
+105% +$85.7M 1.4% 4
2018
Q2 		$81.8M Buy
743,856
+706,933
+1,915% +$73.6M 1.22% 5
2018
Q1 		$3.7M Buy
36,923
+23,647
+178% +$2.42M 0.15% 133
2017
Q4 		$1.31M Buy
13,276
+5,924
+81% +$562K 0.06% 224
2017
Q3 		$691K Sell
7,352
-10,307
-58% -$1.09M 0.03% 254
2017
Q2 		$1.96M Buy
17,659
+177
+1% +$18.7K 0.09% 146
2017
Q1 		$1.71M Sell
17,482
-910,904
-98% -$86.8M 0.08% 158
2016
Q4 		$85.3M Buy
928,386
+5,266
+0.6% +$454K 0.56% 34
2016
Q3 		$78.1M Buy
923,120
+327,519
+55% +$27.5M 0.56% 38
2016
Q2 		$48.5M Buy
+595,601
New +$45.4M 0.41% 51

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Marshall Wace's DGX Position: Q1 2026 in Review

Marshall Wace increased its Quest Diagnostics (DGX) stake by 115% in Q1 2026, buying an estimated $20.8M and bringing the position to 200,278 shares worth $39.3M. The position accounts for 0.04% of the portfolio, ranked #447.

Marshall Wace first reported a position in DGX in Q2 2016 and has held it in 38 quarters since. The position peaked at $165M in Q3 2018. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Marshall Wace held 200,278 shares of Quest Diagnostics worth $39.3M as of Q1 2026.
  • Marshall Wace bought 107,061 Quest Diagnostics shares in Q1 2026, an estimated $20.8M.
  • Quest Diagnostics made up 0.04% of Marshall Wace's portfolio in Q1 2026, its #447 holding.
  • Marshall Wace first reported a position in Quest Diagnostics in Q2 2016 and has held it in 38 quarters since.
  • Marshall Wace's Quest Diagnostics position peaked at $165M in Q3 2018.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.